PALO ALTO, Calif.--(BUSINESS WIRE)--Lux Capital, a leading venture capital firm, today announced the promotions of Zack Schildhorn and Shahin Farshchi, PhD to Partner, and Adam Goulburn, PhD to Principal.
“We’re incredibly proud of the growth and contributions from Zack, Shahin and Adam,” said Peter Hebert, co-founder and Managing Partner of Lux Capital. “Each has proven themselves over a period of years and has demonstrably added value to the firm by actively sourcing, leading and structuring new investments, observing or serving on Boards, recruiting talent, managing teams of people, networking and representing Lux at industry events – all towards helping add value to our portfolio companies and working on behalf of our Limited Partners.”
Zack pioneered Lux’s landscaping of the 3D printing market and sourced the firm’s investment in Shapeways, as well as recently leading both its Seed and Series A investments in SOLS Systems. He holds both a BS and MBA from Cornell University.
Shahin sourced many of Lux’s investments in hardware and devices (including Planet Labs, SiBEAM and Silicon Clocks) and recently led Lux’s new founding investment in Flex Logix. He holds a BS (Berkeley) and MS and PhD (UCLA) in electrical engineering.
Adam has worked closely with Lux’s life sciences portfolio companies and charted Lux’s healthcare IT initiative. He also recently led several recent unannounced healthcare investments. Before joining Lux, Adam was a Postdoctoral Fellow of Neuroscience at Weill Cornell Medical College. He holds dual undergraduate degrees in Commerce and Science, and completed his PhD at the Australian Stem Cell Centre.
About Lux Capital
Lux Capital is a leading venture firm focused on founding, seed and early stage investments in emerging technologies. Lux takes an active role in helping entrepreneurs build successful businesses in Energy, Life Sciences and Technology. The Lux investment team has founded more than 20 companies from scratch, including Caliper, Genocea, Illumina, Kala, Kurion, Lux Research, Nanosys, Neurocrine Biosciences, and Vertex Pharmaceuticals. For more information please visit www.luxcapital.com